VCEL
Vericel Corporation
NASDAQ · Healthcare · Biotechnology · US
$40.19
−0.69%Year over year
Reported trailing growth
- Revenue
- +23.0%
- EBITDA
- +137.5%
- EBIT
- +1428.5%
- EPS
- +241.4%
- Free cash flow
- -22.7%
- Operating cash flow
- +47.5%
Forward estimates
Based on analyst estimates
- Revenue
- +17.9%
- EBITDA
- +64.5%
- EPS
- +46.2%
Three-year CAGR
- Revenue
- +18.9%
- EBITDA
- +225.2%
- EBIT
- +144.4%
- Net income
- +59.4%
- EPS
- +57.1%
- Free cash flow
- +34.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026